Company Overview
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 11.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +65.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.90% |
| 1 Year: | 65.28% |
Stock Price Performance
| 1 Year: | +451.62% |
| 6 Months: | +51.23% |
| 3 Months: | +17.32% |
| 1 Month: | +39.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PVLA Palvella Therapeutics, Inc. R2K | 151.97 | -36.36 | $2.18B | 0.00% | -80.06% | -34.25% | 11.90% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.44M | 11.22M | 7.87M | 7.53M | 4.93M | 14.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -5.76K | -2.20K | -671.22K | -2.77M | -1.84M | -3.70M | -3.53M | -3.88M | -4.38M | -5.80M | -6.18M | -8.01M | -7.89M | -5.18M | -8.14M | -2.24M | -7.80M | -10.68M | -12.23M | -2.91M | -3.86M | -4.66M | -13.00M | -5.06M | -16.76M | -19.01M | -7.46M | -12.33M | -12.17M | -15.51M | 2.06M | -11.81M | -1.76M | -2.91M | -5.06M | -7.87M | -9.25M | -10.18M | -14.86M |
| Net Income | -5.76K | -2.20K | -779.90K | -2.88M | -2.02M | -3.70M | -3.53M | -3.92M | -4.16M | -5.88M | -6.20M | -7.99M | -10.09M | -7.06M | -8.71M | -203.00K | -6.15M | -10.35M | -11.76M | -2.59M | -3.60M | -4.95M | -14.28M | -4.17M | -15.50M | -16.54M | -5.10M | -10.34M | -9.74M | -13.18M | 3.98M | -10.75M | -2.54M | -4.17M | -6.78M | -8.19M | -9.47M | -11.35M | -15.77M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.26 | -0.07 | -0.25 | -0.24 | -0.07 | -0.14 | - | - | 3.62 | -8.70 | -1.54 | -2.47 | -3.94 | -0.74 | -0.86 | -1.03 | -1.20 |
| R&D Expense | - | - | 1.22M | 1.12M | 926.60K | 1.52M | 1.73M | 2.05M | 3.66M | 4.50M | 4.62M | 5.36M | 5.40M | 6.26M | 7.94M | 9.15M | 11.40M | 14.30M | 13.37M | 13.21M | 12.76M | 11.33M | 11.82M | 16.56M | 15.80M | 18.94M | 14.07M | 11.95M | 13.59M | 13.42M | 14.33M | 9.60M | 984.00K | 1.44M | 3.18M | 4.07M | 5.12M | 6.53M | 9.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.43M | 0 | 5.37M | 2.93M | 5.83M | 25.27M | 27.25M | 43.65M | 29.32M | 31.42M | 25.90M | 42.81M | - | - |
| Operating Income | 553.83K | -15.71K | -7.20M | -13.68M | -22.76M | -14.59M | -30.83M | -27.16M | -33.92M | -51.83M | -43.47M | -11.87M | -14.10M | -38.60M |
| Net Income | 66.20K | -15.71K | -9.85M | -14.06M | -22.80M | -17.65M | -26.75M | -25.47M | -37.23M | -45.74M | -33.28M | 18.69M | -17.43M | -41.72M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.68 | -0.71 | - | 2.17 | -7.83 | -3.71 |
| R&D Expense | 9.41M | - | 5.60M | 8.24M | 19.70M | 22.29M | 41.49M | 55.00M | 46.53M | 66.66M | 52.98M | 8.79M | 8.15M | 22.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | May 2013 | Jun 2013 | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.20K | 7.28M | 11.14K | 21.86M | 33.95M | 35.06M | 103.88M | 141.34M | 143.18M | 141.10M | 105.01M | 153.56M | 95.49M | 7.55M | 88.23M | 59.56M |
| Total Equity | 495.70K | - | 4.73K | 585.01K | 10.01K | 18.01M | 31.13M | 25.23M | 11.52M | 39.94M | 38.29M | 51.35M | 31.03M | 50.76M | -93.78M | -74.48M | 62.61M | 27.98M |
| Cash & Equivalents | 6.33M | 0 | 5.20K | 3.69M | 11.14K | 18.47M | 29.35M | 29.36M | 37.88M | 74.87M | - | 62.26M | 70.44M | 117.76M | 38.63M | 7.35M | 83.60M | 57.98M |
| Total Liabilities | - | - | 474 | 6.69M | 1.12K | 3.85M | 2.82M | 9.84M | 92.35M | 101.41M | 104.88M | 89.75M | 73.98M | 102.81M | 67.56M | 11.43M | 25.63M | 31.58M |
| Current Liabilities | - | - | - | 1.77M | - | 3.52M | 2.80M | 8.38M | 45.77M | 48.08M | - | 27.00M | 22.14M | 50.56M | 36.58M | 2.36M | 12.04M | 11.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -15.06K | - | - | - | 49.75M | -1.07M | -52.47M | -45.90M | -7.66M | -59.93M | -13.70M | -10.84M | -25.01M |
| Investing Cash Flow | - | - | - | - | - | -45.88M | -8.88M | 9.84M | 39.21M | -949.00K | -21.24M | 12.00M | - | - |
| Financing Cash Flow | - | 21.00K | - | - | - | 4.09M | 48.51M | 32.17M | 10.12M | 59.13M | 7.21M | 5.00M | 87.09M | -660.00K |
| Capital Expenditure | -49.47K | -0 | -267.41K | -620.75K | -560.00K | -1.95M | -1.70M | -2.46M | -2.73M | -949.00K | -1.04M | -171.00K | - | - |
| Free Cash Flow | - | -15.06K | - | - | - | 47.80M | -2.76M | -54.93M | -48.62M | -8.61M | -60.97M | -13.87M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Jun 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 4.5% | - | -134.2% | -466.6% | -390.3% | -57.7% | -113.1% | -62.2% | -115.7% | -165.0% | -167.8% | -27.7% | - | - |
| Net Margin % | 0.5% | - | -183.6% | -479.5% | -391.0% | -69.8% | -98.2% | -58.4% | -127.0% | -145.6% | -128.5% | 43.7% | - | - |
| ROE % | 11.3% | -156.9% | -54.7% | -45.2% | -90.4% | -153.2% | -67.0% | -49.6% | -120.0% | -90.1% | 35.5% | -25.1% | -27.8% | -149.1% |
| ROCE % | 10.1% | - | -39.2% | -43.9% | -85.3% | -25.1% | -33.1% | -23.8% | -40.9% | -50.3% | -73.8% | -228.8% | -18.5% | -80.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 8.04% | 1.15M | $174.58M |
| 2 | First Light Asset Management, LLC | 6.84% | 980.76K | $148.43M |
| 3 | BVF Inc. | 6.70% | 960.99K | $145.44M |
| 4 | Frazier Life Sciences Management, L.P. | 6.15% | 882.40K | $133.55M |
| 5 | Blackrock Inc. | 4.79% | 686.85K | $103.95M |
| 6 | Jennison Associates LLC | 4.47% | 640.61K | $96.95M |
| 7 | Vanguard Capital Management LLC | 3.33% | 477.29K | $72.24M |
| 8 | State Street Corporation | 3.20% | 459.00K | $69.47M |
| 9 | Federated Hermes, Inc. | 3.02% | 433.01K | $65.53M |
| 10 | Price (T.Rowe) Associates Inc | 2.81% | 402.56K | $60.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PVLA
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQT216V25TWWNBOFI5Q1ZJR2phRUI5RkZ2SG0ydy1GZUtzQXduR0ItbkszemdGOGZVbHk0TmRiMkYxdUp3VDY1T2s1dnhsaURyXzdrRmFVb3pwNjBsaFphWUpubUJLcFRhc1pwY2VjMXl0ZzRqckZaMXdGcWl5bWhrU1FaUUtxVjF0Y2JKQy…
How Pieris Pharmaceuticals Inc. (PVLA) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQS1prWXF4VWZEa08wQzBteXBNck5TSGtJN24xWmxObVhWTnNaNXUxenJXekV1Q2s5ZkN5N2hvUmg1cks0R1MtU0I1ZFY5VGVuSldzMzNnUThxZjQ1SFdKYWgySHR6aHJ3VERKUjVqNTBLQmo1OGFUT1dGejJfSDR2WFk2dzJhYWZoUS1INU…
$PVLA stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOcW1tVFdHbmFPU2ExWkY5NzNqSGtfNnJsYjlqUTJHYlNhZkJnMDRId1JqdHE2a2tjdjVLUFI3aEJkZkMwZl85MmdXWm9vaDV1NGdLTVpIOXc5WndhaGtYVjFRVlZpbm5hR1cwMmN3MUVGbnQ5dmtWYTNrTGJVdWlSMGZWWS1PcTVaVGlwZW…
Palvella Therapeutics Adds Industry Veteran to Board - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUi1ma2ZBNDgydDFMTXZ1Xzg0OFFRdW1fV0ZtSG91RFdPWHMydVFBWjJEcVRjWTFoRVdmMUNkM2ZoUmZDa05vN0lndG90N1ozaVBYczBicG9jVlNWR0MyOWVYMXpDci04N3FSU0xnam9PcnhLQnZCQ3BFTU5za284di1vMG5ybUJ6TGJjVn…
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbFpaanNtVUFNU0ZFWlFOV0F5bWVaQTQycnd6SHJEaFNRaElOTVJYZ1l5ajItLW5kSVRENnJwMTI2UWp6WVVYRGVxMVdYNlJCVmNCREg5VXVCSkE5VHlzYVpqcDc5VzZFWVJiOFRUMk9WYkJPejE5MVpaaHVsQTlSNXYyVjRNeVJVWlpXUy…
Palvella Therapeutics (PVLA) Faces Pullback After Recent Gains – Key Support Levels in Focus - Revenue Growth Stocks - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQR2duQlVxcFY3cVk5Zzlfd25DRE01Z19XczBKVjlKUWlFOTZOMzBBTFkxcXFsVUh4bUQxdWNyWTdwN2RfSFduN3dsV3NyYk1MaDR6QnRpc0pJQUVCQnRpRUJ3bnd0SHRMRjJ2WGZKRW15bERXdy1rcERxbURHUTg4WHVJeGRjcmlLelhzSG…
PVLA — Frequently Asked Questions
What is the current share price of Palvella Therapeutics, Inc. (PVLA)?
As of 2026-07-15 16:51 PDT, Palvella Therapeutics, Inc. (PVLA) trades at $151.97 on NasdaqGM. Its 52-week range is $27.55 to $154.84.
What is the market capitalisation of PVLA?
Palvella Therapeutics, Inc. (PVLA) has a market capitalisation of $2.18B on NasdaqGM.
What is the P/E ratio of PVLA?
PVLA trades at a trailing price-to-earnings (P/E) ratio of -36.36. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 9.33.
What is the return on equity (ROE) of PVLA?
PVLA has a return on equity (ROE) of -34.25%. Its return on capital employed (ROCE) is -80.06%.
Is PVLA a good stock to buy?
This page provides a data-driven analysis of Palvella Therapeutics, Inc. (PVLA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.